Advanced search
Publication Cover
Postgraduate Medicine Volume 125, 2013 - Issue 1
Submit an article Journal homepage
273
Views
40
CrossRef citations to date
0
Altmetric
Clinical Features

Preservation of Renal Function during Gout Treatment with Febuxostat: A Quantitative Study

Andrew Whelton Director, Universal Clinical Research Center, Inc., Hunt Valley, MD; Professor of Medicine/Adjunct, The Johns Hopkins University School of Medicine, Baltimore, MDCorrespondence[email protected]
, MD,
Patricia A. MacDonald Associate Director, Medical Affairs, US Region, Takeda Pharmaceuticals International, Inc, Deerfield, IL
, NP,
Solomon Chefo Project Statistician, Takeda Global Research and Development Center, Inc, Deerfield, IL
, PhD &
Lhanoo Gunawardhana Medical Director, Immunology and Inflammation, Clinical Science, Takeda Global Research and Development Center, Inc, Deerfield, IL
, MD, PhD
Pages 106-114 | Published online: 13 Mar 2015

Citations (40)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Yanxia Wu, Qianqian Chen, Qionghua Zhang, Yanli Wu & Xujuan Zheng. (2023) A 5-Year Follow-Up Study to Explore Factors Associated with Rapid Kidney Function Decline Among Bus Drivers. International Journal of General Medicine 16, pages 3193-3201.
Read now
Richard Sheer, Kyle D Null, Keith A Szymanski, Lavanya Sudharshan, Jennifer Banovic & Margaret K Pasquale. (2017) Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat. ClinicoEconomics and Outcomes Research 9, pages 629-639.
Read now
Lee J. Smolen, James C. Gahn, Ghaith Mitri & Aki Shiozawa. (2016) Febuxostat in the management of gout: a cost-effectiveness analysis. Journal of Medical Economics 19:3, pages 265-276.
Read now
A. Stack, A.J. Manolis & E. Ritz. (2015) Detrimental role of hyperuricemia on the cardio-reno-vascular system. Current Medical Research and Opinion 31:sup2, pages 21-26.
Read now

Articles from other publishers (36)

E. V. Cheremushkina & M. S. Eliseev. (2022) Hyperuricemia and gout: effects on bone and articular cartilage (literature review). Obesity and metabolism 19:3, pages 348-357.
Crossref
A. B. Bashkova & I. V. Madyanov. (2022) Febuxostat as an effective drug of choice for urate-lowering therapy for gout (case report). Meditsinskiy sovet = Medical Council:14, pages 137-144.
Crossref
Abbasi Muhammad Tanzeel, Asghar Muhammad Rashid, Bashir Khuram & Hashmi Muhammad Nauman. (2021) Hyperuricemia in Renal patients: Treat or not to treat. Archives of Clinical Nephrology, pages 050-056.
Crossref
Api Chewcharat, Yawen Chen, Charat Thongprayoon, Andrew M. Harrison, Michael A. Mao & Wisit Cheungpasitporn. (2021) Febuxostat as a renoprotective agent for treatment of hyperuricaemia: a meta‐analysis of randomised controlled trials. Internal Medicine Journal 51:5, pages 752-762.
Crossref
M. S. Eliseev. (2020) Commentaries on the updated American College of Rheumatology guidelines for the management of gout. Urate-lowering drugs (Part 1). Modern Rheumatology Journal 14:3, pages 117-124.
Crossref
Zhong-Yuan ChengYou-Zhen FengXiao-Ling Liu, Yao-Jiang Ye, Jun-Jiao Hu & Xiang-Ran Cai. (2019) Diffusional kurtosis imaging of kidneys in patients with hyperuricemia: initial study. Acta Radiologica 61:6, pages 839-847.
Crossref
Ryuichi Kawamoto, Daisuke Ninomiya, Taichi Akase, Asuka Kikuchi & Teru Kumagi. (2019) Interactive association of baseline and changes in serum uric acid on renal dysfunction among community‐dwelling persons. Journal of Clinical Laboratory Analysis 34:5.
Crossref
Irina E Chazova, Juliya V Zhernakova, Oksana A Kisliak, Sergey V Nedogoda, Valery I Podzolkov, Elena V Oshchepkova, Irina V Medvedeva, Olga Iu Mironova & Nataliia V Blinova. (2019) Consensus on patients with hyperuricemia and high cardiovascular risk treatment. Systemic Hypertension 16:4, pages 8-21.
Crossref
Amayelle Rey, Benjamin Batteux, Solène M. Laville, Justine Marienne, Kamel Masmoudi, Valérie Gras-Champel & Sophie Liabeuf. (2019) Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study. Arthritis Research & Therapy 21:1.
Crossref
Chien-Hsing Wu, Chih-Chao Yang, Hsueh-Wen Chang, Bin Huang, Chung-Jen Chen, Eton I-Cheng Lin, Chien-Yi Wu, Yueh-Hua Chung, Yu-Han Hsu, Chien-Te Lee & Feng-Rong Chuang. (2019) Urinary Uromodulin/Creatinine Ratio as a Potential Clinical Biomarker for Chronic Kidney Disease Patients with Gout: A Pilot Study. Medical Principles and Practice 28:3, pages 273-279.
Crossref
Kenneth G. Saag, Michael A. Becker, Andrew Whelton, Barbara Hunt, Majin Castillo, Krisztina Kisfalvi & Lhanoo Gunawardhana. (2018) Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo‐Controlled Study . Arthritis & Rheumatology 71:1, pages 143-153.
Crossref
Lhanoo Gunawardhana, Michael A. Becker, Andrew Whelton, Barbara Hunt, Majin Castillo & Kenneth Saag. (2018) Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study. Arthritis Research & Therapy 20:1.
Crossref
Kristen Davies & Marwan A S Bukhari. (2018) Recent pharmacological advances in the management of gout. Rheumatology 57:6, pages 951-958.
Crossref
S. Timilsina, K. Brittan, J.R. O'Dell, M. Brophy, A. Davis-Karim, A.M. Henrie, T. Neogi, J. Newcomb, P.M. Palevsky, M.H. Pillinger, D. Pittman, T.H. Taylor, H. Wu & T.R. Mikuls. (2018) Design and Rationale for the Veterans Affairs “Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat” Trial. Contemporary Clinical Trials 68, pages 102-108.
Crossref
Xiang Xia Zeng, Yunliang Tang, Kaixiang Hu, Xi Zhou, Jiao Wang, Lingyan Zhu, Jianying Liu & Jixiong Xu. (2018) Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease. Medicine 97:13, pages e0161.
Crossref
Natalia O. Litbarg. 2018. Integrative Medicine. Integrative Medicine 411 421.e11 .
Binoy J. Paul, K. Anoopkumar & Vinod Krishnan. (2017) Asymptomatic hyperuricemia: is it time to intervene?. Clinical Rheumatology 36:12, pages 2637-2644.
Crossref
Lhanoo Gunawardhana, Lachy McLean, Henry A. Punzi, Barbara Hunt, Robert N. Palmer, Andrew Whelton & Daniel I. Feig. (2017) Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo‐Controlled Study. Journal of the American Heart Association 6:11.
Crossref
Ana Beatriz Vargas-Santos & Tuhina Neogi. (2017) Management of Gout and Hyperuricemia in CKD. American Journal of Kidney Diseases 70:3, pages 422-439.
Crossref
In-Chang ChoSeung Ki Min. (2017) Hyperuricemia and Urologic Disease. Urogenital Tract Infection 12:3, pages 103.
Crossref
Christopher M. Burns & Robert L. Wortmann. 2017. Kelley and Firestein's Textbook of Rheumatology. Kelley and Firestein's Textbook of Rheumatology 1620 1644.e4 .
Thomas Berger. (2016) Asymptomatische Hyperurikämie und Herz-Kreislauf-ErkrankungenAsymptomatic hyperuricemia and cardiovascular diseases. rheuma plus 15:3, pages 76-79.
Crossref
Kenneth G. Saag, Andrew Whelton, Michael A. Becker, Patricia MacDonald, Barbara Hunt & Lhanoo Gunawardhana. (2016) Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment. Arthritis & Rheumatology 68:8, pages 2035-2043.
Crossref
Jan T. Kielstein & Anne-Kathrin Tausche. (2016) The Relevance of Hyperuricaemia. EMJ Rheumatology, pages 100-104.
Crossref
Gerald Levy & T. Craig Cheetham. (2015) Is It Time to Start Treating Asymptomatic Hyperuricemia?. American Journal of Kidney Diseases 66:6, pages 933-935.
Crossref
Dipankar Sircar, Soumya Chatterjee, Rajesh Waikhom, Vishal Golay, Arpita Raychaudhury, Suparna Chatterjee & Rajendra Pandey. (2015) Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial. American Journal of Kidney Diseases 66:6, pages 945-950.
Crossref
Kenichi Tanaka, Masaaki Nakayama, Makoto Kanno, Hiroshi Kimura, Kimio Watanabe, Yoshihiro Tani, Yoshimitsu Hayashi, Koichi Asahi, Hiroyuki Terawaki & Tsuyoshi Watanabe. (2015) Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. Clinical and Experimental Nephrology 19:6, pages 1044-1053.
Crossref
Claudio Borghi, Enrico Agabiti Rosei, Thomas Bardin, Jesse Dawson, Anna Dominiczak, Jan T. Kielstein, Athanasios J. Manolis, Fernando Perez-Ruiz & Giuseppe Mancia. (2015) Serum uric acid and the risk of cardiovascular and renal disease. Journal of Hypertension 33:9, pages 1729-1741.
Crossref
James E. Frampton. (2015) Febuxostat: A Review of Its Use in the Treatment of Hyperuricaemia in Patients with Gout. Drugs 75:4, pages 427-438.
Crossref
Huaxiang Wu, Jing Xue, Lu Ye, Qijing Zhou, Dan Shi & Rongzhen Xu. (2014) The application of dual-energy computed tomography in the diagnosis of acute gouty arthritis. Clinical Rheumatology 33:7, pages 975-979.
Crossref
Hyun Ah Kim, Young-Il Seo & Yeong W. Song. (2014) Four-Week Effects of Allopurinol and Febuxostat Treatments on Blood Pressure and Serum Creatinine Level in Gouty Men. Journal of Korean Medical Science 29:8, pages 1077.
Crossref
Robert A Yood, Faith D Ottery, William Irish & Marsha Wolfson. (2014) Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials. BMC Research Notes 7:1, pages 54.
Crossref
Anne-Kathrin Tausche, Monika Reuss-Borst & Ute Koch. (2014) Urate Lowering Therapy with Febuxostat in Daily Practice—A Multicentre, Open-Label, Prospective Observational Study. International Journal of Rheumatology 2014, pages 1-6.
Crossref
G. Masclee. 2014. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions 119 137 .
A.-K. Tausche, M. Christoph, M. Forkmann, U. Richter, S. Kopprasch, C. Bielitz, M. Aringer & C. Wunderlich. (2013) As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout. Rheumatology International 34:1, pages 101-109.
Crossref
Jan T. Kielstein. 2014. Management of Chronic Kidney Disease. Management of Chronic Kidney Disease 355 362 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.